Cecilia Kanyama

Lilongwe, C, Malawi

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

An exploratory, qualitative study of treatment preferences among participants in a TB therapeutic trial.

An exploratory, qualitative study of treatment preferences among participants in a TB therapeutic trial.

Journal: IJTLD open

Published: March 28, 2026

"Six months is a lot of time to lie": Anticipated stigma, disclosure and treatment preferences among participants in a tuberculosis therapeutic trial.

"Six months is a lot of time to lie": Anticipated stigma, disclosure and treatment preferences among participants in a tuberculosis therapeutic trial.

Journal: Research square

Published: January 09, 2026

An audit of the HIV drug resistance testing program in Malawi.

An audit of the HIV drug resistance testing program in Malawi.

Journal: Malawi medical journal : the journal of Medical Association of Malawi

Published: November 27, 2025

Pharmacokinetic modelling as a tool to assess TB treatment adherence: application to the REMEMBER study.

Pharmacokinetic modelling as a tool to assess TB treatment adherence: application to the REMEMBER study.

Journal: IJTLD open

Published: July 22, 2025

Social and Structural Interventions to Reduce Strikingly High Post-Hospital Mortality for People Living with HIV in Sub-Saharan Africa.

Social and Structural Interventions to Reduce Strikingly High Post-Hospital Mortality for People Living with HIV in Sub-Saharan Africa.

Journal: Current HIV/AIDS reports

Published: July 21, 2025

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.

Journal: The Lancet. Infectious diseases

Published: April 17, 2025

ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis.

ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis.

Journal: Research square

Published: April 08, 2025

Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial.

Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial.

Journal: The lancet. HIV

Published: February 20, 2025

ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis.

ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis.

Journal: Trials

Published: January 30, 2025

Household economic impact of HIV-associated cryptococcal meningitis in five countries in Southern and Eastern Africa.

Household economic impact of HIV-associated cryptococcal meningitis in five countries in Southern and Eastern Africa.

Journal: Journal of the International AIDS Society

Published: August 01, 2024

Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trials.

Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trials.

Journal: The Lancet. Global health

Published: July 26, 2024

Recent Antiretroviral Therapy Initiation Is Associated With Increased Mortality Risk in HIV-associated Cryptococcal Meningitis: An Analysis of Clinical Trial Data From Africa.

Recent Antiretroviral Therapy Initiation Is Associated With Increased Mortality Risk in HIV-associated Cryptococcal Meningitis: An Analysis of Clinical Trial Data From Africa.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: May 17, 2024

Showing 1-12 of 67

Last Updated: 09/26/2026